Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28566174 | 0.90 | HTR6 (0.41) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL29443418 | 0.88 | HTR6 (0.39) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL29719476 | 0.88 | HTR6 (0.39) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL18196939 | 0.88 | HTR6 (0.39) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL29201776 | 0.87 | HTR6 (0.38) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL19385615 | 0.87 | HTR6 (0.40) | HTR6MEN1GFERKMT2AHTR2A | |
| SCHEMBL19385624 | 0.86 | HTR6 (0.38) | HTR6MEN1GFERKMT2AHTR2A | |
| Abeprazan SCHEMBL29201774 | 0.86 | HTR6 (0.37) | HTR6MEN1GFERKMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL19385754 | 0.85 | HTR6 (0.38) | HTR6MEN1GFERKMT2AHTR2A | |
| SCHEMBL19385605 | 0.84 | MEN1 (0.42) | HTR6MEN1GFERKMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854784-A1 | METHOD FOR PRODUCING 4-METHOXY PYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-28 | — | — | EP | disclosed |
| US-20210221770-A1 | MANUFACTURING METHOD FOR 4-METHOXYPYRROLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221770-A1 | MANUFACTURING METHOD FOR 4-METHOXYPYRROLE DERIVATIVES | COMT, TH, HPD | HTR6 582/4885MEN1 2718/4885GFER 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.